Search clinical trials for: Everolmus

Total 919 results

Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Seung-Jung Park
Abbott Medical Devices; CardioVascular Research Foundation, Korea

Terminated

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST) (BEST)

Coronary Artery Disease

Thailand, Korea, Republic of, China, Malaysia
Novartis Pharmaceuticals

Completed

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (OSAT)

Metastatic Renal Cell Carcinoma (mRCC)

Norway
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (TRACER)

Hepatocellular Carcinoma

Hong Kong, Taiwan, Thailand
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
German Breast Group
Novartis

Terminated

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (Evelyn)

Metastatic Breast Cancer

Germany
University of Luebeck

Terminated

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion (SCORE-CTO)

Coronary Artery Disease

Germany
Guangdong Provincial People's Hospital
Novartis

Unknown

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Neuroendocrine Tumors | Carcinoid Tumor

China
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (COOPERATE-1)

Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Germany
Leiden University Medical Center

Unknown

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Head and Neck Cancer

Netherlands
Novartis Pharmaceuticals

Terminated

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (CATChEz)

Carcinoma, Renal Cell

Australia, Korea, Republic of
Centre Leon Berard

Suspended

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (CHONRAD)

Chondrosarcoma

France
German Breast Group
Novartis

Completed

Dose EScalation Induction of EvERolimus (Desiree)

Breast Cancer | Hormone Receptor Positive Tumor

Germany
Abbott Medical Devices

Completed

A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System (STRIDES)

Atherosclerosis | Peripheral Vascular Disease

Germany, Austria, Belgium, Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
ARCAGY/ GINECO GROUP

Completed

Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer (ENDORAD)

Endometrial Cancer

France
Yonsei University

Unknown

Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation (ANCHOR)

Coronary Artery Disease

Korea, Republic of
Asan Medical Center

Completed

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Stomach Neoplasm

Korea, Republic of
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Solid Tumor

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma

China
Asan Medical Center

Completed

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Stomach Neoplasm

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Israel
Bayside Health

Unknown

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Australia
Yonsei University

Completed

A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Epilepsy and Focal Cortical Dysplasia II

Korea, Republic of
Cardiff University
Novartis

Unknown

A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis (TRON)

Tuberous Sclerosis

United Kingdom
Julie E. Bauman, MD, MPH
Novartis

Terminated

Phase II Study of RAD001 Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC)

Germany
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
Umberto I Hospital, Frosinone Italy

Unknown

Study of ABSORB Stent in Acute Myocardial Infarction (ABSORB-ACS)

Acute Myocardial Infarction | Artery; Deformity, Coronary (Acquired)

Italy
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

Belgium, Italy, Poland, Sweden, France
Abbott Medical Devices

Terminated

The ABSORB BTK (Below The Knee) Clinical Investigation

Atherosclerosis | Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Claudication | Critical Limb Ischemia | PAD | PVD | Lower Limb Disease | PAOD

Belgium
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
Seagen Inc.

Terminated

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
North Texas Veterans Healthcare System

Completed

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study (ACE-CTO)

Coronary Occlusions

United States
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Tuberous Sclerosis | Angiolipoma

United States
Samsung Medical Center

Completed

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

Korea, Republic of
Technical University of Munich

Completed

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Germany
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Radboud University Medical Center
Novartis

Completed

Influence of Exceptional Patient Characteristics on Everolimus Exposure (INPRES)

Breast Neoplasms

Netherlands
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia

Search clinical trials for: Everolmus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations